Don’t Get Blindsided by Emerging Targets

Imalumab is the only drug targeting oxMIF to reach clinical trials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they have invested in three different modalities targeting oxMIF via distinct mechanisms of action, see link below.

Through AI technology, Kognitic’s platform will automatically capture the emergence of assets directed at this under-the-radar target and details of their clinical trials, such as other drugs/targets they’re combining with, relevant patient segmentations, and critical events for those trials. Clients leveraging Kognitic’s platform will be first to know if these assets are doomed to the same fate as imalumab, or if in oxMIF lies an investment opportunity.

https://endpts.com/former-shire-execs-set-up-shop-to-take-a-shot-at-under-the-radar-cancer-target/